Piers Morgan has shared a nostalgic moment on Instagram, featuring Hollywood stars Bruce Willis, Sylvester Stallone, and ...

Just a few days after scientists announced we're at a pivotal tipping point in Alzheimer's disease research, a team has made ...

An update from Passage Bio ( ($PASG) ) is now available. On August 12, 2025, Passage Bio reported its second quarter financial results and ...

Piers Morgan is looking back on the heyday of Hollywood.

Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing ...

Targeting cellular structures called nuclear speckles could be a completely new approach for treating proteinopathies, ...

Researchers at Boston University Chobanian & Avedisian School of Medicine have built an artificial intelligence tool that can ...

Tividenofusp alfa BLA for Hunter syndrome accepted for priority review and assigned PDUFA target action date of January 5, 2026; company preparing for commercial launchDNL126 accelerated approval path ...

A groundbreaking study reveals that reshaping nuclear speckles — tiny structures inside cell nuclei that regulate protein maintenance — could be a novel way to treat proteinopathies like Alzheimer’s, ...

Tividenofusp alfa BLA for Hunter syndrome accepted for priority review and assigned PDUFA target action date of January 5, 2026; company preparing for commercial launchDNL126 accelerated approval path ...

PHILADELPHIA, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, ...

Given the success of the previous edition of this Research Topic, we are pleased to announce the release of its third volume. Anosognosia or lack of ...